Currently Viewing:
ISPOR 2019
Panelists Discuss the Potential and Pitfalls of Disruption in Healthcare
May 20, 2019
Trends in Value That Dr Daniel Mullins Expects to See in Coming Years
May 21, 2019
Dr Jon Campbell Discusses the Need for More Creative Methods of Value Assessment
May 21, 2019
Currently Reading
The Imperfect QALY: How It's Used Depends on Where You Enter Value Discussions
May 21, 2019
Panelists Debate the Role of ICER: Useful Overseer of Prices, or Oppressor of Choice?
May 22, 2019
Bringing Financial Theory Into the Value Equation of Future Cutting-Edge Therapies
May 22, 2019
Dr Devin Incerti Outlines Best Practices for Approaching Value Assessment
May 22, 2019
Biosimilar Experts Give Highlights of US Uptake Issues
May 23, 2019
Dr Nicholas Robert Explains the Benefits, Challenges of Using RWE for Measuring Clinical End Points
May 23, 2019
Dr Eleanor Perfetto Outlines Criticisms of the QALY
May 23, 2019
New Therapies Offer Possible Cures but Pose Affordability Challenges
May 23, 2019
Fremanezumab Cost Effective for Both Types of Migraine, Researchers Say
May 27, 2019
Dr Jon Campbell on Benefits of Using MCDA in Value Assessment
June 03, 2019
Dr Nicholas Robert Explains the Need to Standardize Use of RWE for Measuring Clinical End Points
June 23, 2019
Dr Devin Incerti: Use Value Assessments to Maximize the Well-Being of a Population
July 14, 2019
Dr Nicholas Robert Discusses How Real-World Data Can Complement Clinical Trial Data
July 16, 2019
Dr Eleanor Perfetto on Ways to Improve Transparency, Education Around Value Assessment
July 23, 2019
Dr Nicholas Robert on Lag Time Between Drug Approval, Availability of the Drug in EMRs
July 29, 2019
Dr Nicholas Robert: Lag Time Between a Drug Approval, Availability in EMRs Can Impact Patient Care
August 10, 2019
Dr Nicholas Robert Outlines How Patients Can Provide More Information on Newly Approved Drugs
August 22, 2019

The Imperfect QALY: How It's Used Depends on Where You Enter Value Discussions

Allison Inserro
Panelists at a session of the ISPOR 2019 annual meeting discussed the good and the bad about the quality-adjusted life-year (QALY) metric from their various perspectives.
What is the value of the quality-adjusted life-years (QALYs) metric, and is it perfect as is, or does it need to be changed? Should it be scrapped altogether? Depending on one’s perspective (payer vs patient advocacy group, for example) the QALY connotes different things. At a session “The Controversial QALY: Is There a Middle Ground in the Debate?” during the ISPOR 2019 annual meeting, panelists discussed the good and the bad about the QALY metric from their various perspectives.

The panel was moderated by Jennifer Bright, MPA, the executive director of Innovation and Value Initiative; she was joined by Lou Garrison, PhD, the assistant director of the Pharmaceutical Outcomes Research and Policy Program at the University of Washington; Eleanor M. Perfetto, PhD, MS, the executive vice president of the National Health Council; and Andrew Lloyd, DPhil, a health economics consultant from the United Kingdom.

"I view it as a pragmatic approximation,” said Garrison, who was co-chair of an ISPOR task force on value assessment frameworks.

Consumers are insulated from the price of pharmaceuticals because of health insurance, he said, so traditional economic theory about pricing does not hold when it comes to this industry, he said. In his view, the QALY is a work-around to try and figure out what value is and what should be rewarded. But as a practice in the US, despite the vast amounts of research, policymakers don’t take it into consideration.

He cited 2 problems—value is not highly correlated with price, and there is a lack of real world evidence after launch.

“The US is a very friendly market, everything gets into the market,” Garrison said, as opposed to other countries that are not as willing to pay for every therapy.

From the patient advocacy perspective, Perfetto said the concern about value frameworks is that the patient voice was not present when these were being created. Without the involvement of patients, wrong endpoints will give the wrong answer, she said.

There is fear of access to therapy being cut off, depending on what a report says about QALY and value, she said. “Frankly, the reports get used and they get cherry picked,” she said.

Payers could “hide behind” such pricing reports, Perfetto said. And with decisions like CVS Health deciding to use reports from the Institute for Clinical and Economic Review in formulary decisions, there is concern that the reports are used as a “blunt instrument.”

For instance, a section of a report that says step therapy should never be used may never be used by a payer, she said.  

Bringing a different perspective as a resident of the United Kingdom, Lloyd said he focuses on what a treatment does for a patient’s length of life and quality of life. Value “shouldn’t be about rewarding innovation—it should be about purchasing health.”

“I just want to know how much benefit it’s going to give to patients,” he said, and added that he places much less emphasis on innovation.

Bright asked if the controversy and debate about QALY is one of use or one of method.

“I would say it’s both,” said Perfetto, who questioned the use of outdated data.

Garrison took a slightly more different view, saying that the reports start with a review of clinical data and conduct a literature review that comes before a QALY is ever developed. He also reiterated his view that it is not even used much beyond those involved in research.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up